睿知中国疾病研究地图
候选清单0

兰州

兰州大学第二医院

Lanzhou University Second Hospital

在本站收录的 53 种疾病中,这家医院列在其中 19 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

兰州大学第二医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma10 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma45 篇牵头论文
  3. 胃癌Stomach cancer108 篇牵头论文
  4. 脊索瘤Chordoma1 篇牵头论文
  5. 骨肉瘤Osteosarcoma15 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour5 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  8. 尤文肉瘤Ewing sarcoma2 篇牵头论文
  9. 多发性骨髓瘤Multiple myeloma12 篇牵头论文
  10. IgG4相关性疾病IgG4-related disease2 篇牵头论文
  11. 重症肌无力Myasthenia gravis2 篇牵头论文
  12. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
  13. 大动脉炎Takayasu arteritis0 篇牵头论文
  14. 特发性肺纤维化Idiopathic pulmonary fibrosis0 篇牵头论文
  15. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  16. IgA 肾病IgA nephropathy2 篇牵头论文
  17. 戈谢病Gaucher disease0 篇牵头论文
  18. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  19. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、视网膜母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、烟雾病、肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.3%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 2220232024: 1120242025: 222025

兰州有 3 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题新辅助与综合治疗分子标志物与基因影像与人工智能
论文中的科室肿瘤内科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文10
  1. Predictive value of 18F-FDG PET/CT-based radiomics model for lymph node metastasis in esophageal squamous cell carcinoma.2026Annals of nuclear medicine
  2. BRD4 Induces Esophageal Squamous Cell Carcinoma Progression via the Wnt/β-catenin Pathway.2026Biochemical genetics免费全文
  3. Neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study with 2-year survival analysis.2025Journal of cancer research and clinical oncology免费全文
  4. PYCR1 Promotes Esophageal Squamous Cell Carcinoma by Interacting With EGFR to Affecting the PI3K/Akt/mTOR Signaling Pathway.2025The journal of gene medicine
  5. Downregulation of ALDH5A1 suppresses cisplatin resistance in esophageal squamous cell carcinoma by regulating ferroptosis signaling pathways.2024Molecular carcinogenesis
  6. Utility of near-infrared fluorescence imaging with indocyanine green in resection of oesophageal squamous cell carcinoma: A literature review and a case report.2023Photodiagnosis and photodynamic therapy
  7. Molecular mechanism underlying epithelial-mesenchymal transformation and cisplatin resistance in esophageal squamous cell carcinoma.2023Thoracic cancer免费全文
  8. Epithelial-Mesenchymal Transition Gene Signature Is Associated with Neoadjuvant Chemoradiotherapy Resistance and Prognosis of Esophageal Squamous Cell Carcinoma.2022Disease markers免费全文
  9. Long non‑coding RNA PART1: dual role in cancer.2022Human cell
  10. SYNGR2 serves as a prognostic biomarker and correlates with immune infiltrates in esophageal squamous cell carcinoma.2022The journal of gene medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  2. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
PubMed 以外找到的论文(未计入)1
  1. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 45 篇,占 0.3%。

牵头论文
45
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 7720222023: 101020232024: 7720242025: 15152025

兰州有 2 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室普外/肝胆胰外科病理/检验科影像/核医学科肿瘤内科
牵头的论文45
  1. Whole-lesion iodine map histogram analysis combined with focal ROI iodine concentrations for preoperative prediction of cytokeratin 19-positive hepatocellular carcinoma.2026Abdominal radiology (New York)
  2. Deep learning 3D super-resolution radiomics model based on Gd-enhanced MRI for improving preoperative prediction of HCC pathological grading.2026Abdominal radiology (New York)
  3. Prediction of Posthepatectomy Liver Failure in Narrow Resection Margins HCC: A Model Based on Iodine Map Histogram Analysis of Nontumorous Liver Parenchyma.2025Academic radiology
  4. Comprehensive molecular characteristics of hepatocellular carcinoma based on multi-omics analysis.2025BMC cancer免费全文
  5. Visit‑to‑visit variability of inflammation-immunity indices and prognosis in hepatocellular carcinoma.2025BMC gastroenterology免费全文
  6. Adherence to STARD guidelines in miRNA diagnostic accuracy studies for hepatocellular carcinoma: a systematic review.2025BMC medical research methodology免费全文
  7. Study on the concordance in the diagnostic efficacy between CEUS LI-RADS and CT/MR LI-RADS for HCC.2025Clinical hemorheology and microcirculation
  8. Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets.2025Hepatology international
  9. APM-Related gene signature model to predict prognosis and immunotherapy response in hepatocellular carcinoma.2025Human genetics
  10. Therapeutic targets for hepatocellular carcinoma identified using proteomics and Mendelian randomization.2025Journal of gastroenterology and hepatology
  11. A spreadable self-gelling hemostatic powder sensitizes CAR-NK cell therapy to prevent hepatocellular carcinoma recurrence postresection.2025Journal of nanobiotechnology免费全文
  12. Post-translational modifications in hepatocellular carcinoma: mechanisms and therapeutic potential.2025Medical oncology (Northwood, London, England)
  13. Causal relationship between serum bilirubin, cholelithiasis and hepatobiliary and pancreatic malignancy: A bidirectional and 2-sample Mendelian randomization study.2025Medicine免费全文
  14. A contrast‑enhanced CT histogram‑driven nomogram for predicting post‑radiotherapy liver regeneration in hepatocellular carcinoma.2025Radiation oncology (London, England)免费全文
  15. Integrating single-cell RNA sequencing, WGCNA, and machine learning to identify key biomarkers in hepatocellular carcinoma.2025Scientific reports免费全文
  16. Progress of Pyruvate Kinase M2 in Hepatocellular Carcinoma-Associated Signaling Pathway.2025Tissue engineering. Part C, Methods
  17. P2RX4 promotes hepatocellular carcinoma progression via calcium-mediated PI3K/AKT activation and immune remodeling.2025World journal of surgical oncology免费全文
  18. Alpha-fetoprotein upregulates hepatocellular carcinoma cell-intrinsic PD-1 expression through the LATS2/YAP/TEAD1 pathway.2024Biochimica et biophysica acta. General subjects
  19. The Role of Pyruvate Kinase M2 Posttranslational Modification in the Occurrence and Development of Hepatocellular Carcinoma.2024Cell biochemistry and function
  20. FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.2024Journal for immunotherapy of cancer免费全文
  21. Prognostic Significance of Iron Metabolism and Immune-Related Genes as Risk Markers in Hepatocellular Carcinoma.2024Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  22. Integrative analysis of multi-omics data identified PLG as key gene related to Anoikis resistance and immune phenotypes in hepatocellular carcinoma.2024Journal of translational medicine免费全文
  23. Transarterial Chemoembolization Combined with Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2024Oncology
  24. Identification and verification of a prognostic autophagy-related gene signature in hepatocellular carcinoma.2024Scientific reports免费全文
  25. Different power modes of microwave ablation for hepatocellular carcinoma: Evaluation of recurrence rate and factors related to recurrence.2023Asian journal of surgery
  26. Development and validation of a coagulation-related genes prognostic model for hepatocellular carcinoma.2023BMC bioinformatics免费全文
  27. MicroRNA-5195-3p mediated malignant biological behaviour of insulin-resistant liver cancer cells via SOX9 and TPM4.2023BMC cancer免费全文
  28. Predicting glypican-3 expression in hepatocellular carcinoma: A comprehensive analysis using combined contrast-enhanced ultrasound and clinical factors.2023Clinical hemorheology and microcirculation
  29. Neutrophil extracellular traps regulating tumorimmunity in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  30. Establishment and characterization of a new Chinese hepatocellular carcinoma cell line, Hep-X1.2023Human cell
  31. PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells.2023Immunological investigations
  32. Predictive Roles of ADAM17 in Patient Survival and Immune Cell Infiltration in Hepatocellular Carcinoma.2023International journal of molecular sciences免费全文
  33. RPS24 Is Associated with a Poor Prognosis and Immune Infiltration in Hepatocellular Carcinoma.2023International journal of molecular sciences免费全文
  34. Contrast-enhanced ultrasound demonstrates greater adjuvant potential: past, current status, and future applications in Hepatocellular carcinoma early diagnosis.2023Medical ultrasonography
  35. BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma.2022APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  36. Study on correlation between two-dimensional ultrasound, contrast-enhanced ultrasound and microvascular invasion in hepatocellular carcinoma.2022Clinical hemorheology and microcirculation
  37. Overexpression of Ribosomal Protein S6 Kinase A4 (RPS6KA4) Predicts a Poor Prognosis in Hepatocellular Carcinoma Patients: A Study Based on TCGA Samples.2022Combinatorial chemistry & high throughput screening
  38. Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory.2022Contrast media & molecular imaging免费全文
  39. The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy.2022Frontiers in endocrinology免费全文
  40. Anticancer Effect of Arbutin on Diethylnitrosamine-Induced Liver Carcinoma in Rats via the GRP and GADD Pathway.2022Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  41. Overexpressed PAQR4 predicts poor overall survival and construction of a prognostic nomogram based on PAQR family for hepatocellular carcinoma.2022Mathematical biosciences and engineering : MBE
  42. Bioinformatic Evidence Reveals that Cell Cycle Correlated Genes Drive the Communication between Tumor Cells and the Tumor Microenvironment and Impact the Outcomes of Hepatocellular Carcinoma.2021BioMed research international免费全文
  43. The lncRNA VPS9D1-AS1 Promotes Hepatocellular Carcinoma Cell Cycle Progression by Regulating the HuR/CDK4 Axis.2021DNA and cell biology
  44. The expression and clinical significance of TPM4 in hepatocellular carcinoma.2021International journal of medical sciences免费全文
  45. Transcript levels of spindle and kinetochore-associated complex 1/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma.2021Scientific reports免费全文
中文论文(未计入)1
  1. [Overexpression of Nei endonuclease VIII-like protein 3 in hepatocellular carcinoma indicates increased levels of immune infiltration and an unfavorable prognosis].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  2. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 108 篇,占 1.1%。

牵头论文
108
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 121220212022: 151520222023: 202020232024: 202020242025: 38382025

兰州有 3 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

  2. 正在招募
    Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2025-04
    登记号
    NCT06925243

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心兰州、广州

  3. 正在招募
    Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2025-05
    登记号
    NCT06949033

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心兰州、广州

  4. 正在招募
    Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
    分期
    III期
    开始
    2025-06
    登记号
    NCT07029269

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心兰州、广州、杭州、福州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物影像与人工智能手术
论文中的科室普外/肝胆胰外科消化/肝病科影像/核医学科肿瘤内科
牵头的论文108
  1. The snoRNA SNORA21 promotes gastric tumorigenesis by attenuating P53 activity through CHK1 phosphorylation inhibition and PERP-dependent feedback loops.2026Cellular signalling
  2. TMEM176A drives anti-apoptotic signaling through TGM2-mediated ERK activation in gastric cancer.2026International immunopharmacology
  3. The Value of Double Contrast-Enhanced Ultrasonography in the Differential Diagnosis of Gastric Submucosal Tumors and the Assessment of the Malignant Risk of Gastrointestinal Stromal Tumors.2026Seminars in ultrasound, CT, and MR
  4. Targeted Dual-Responsive Liposomes Co-Deliver Jolkinolide B and Ce6 to Synergistically Enhance the Photodynamic/Immunotherapy Efficacy in Gastric Cancer through the PANoptosis Pathway.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  5. Identification and prioritization of high-frequency biomarkers and therapeutic targets in gastric cancer trials.2025BMC cancer免费全文
  6. KLC3 drives gastric cancer progression by stabilizing SLC2A5 to activate MAPK signaling and promote epithelial-mesenchymal transition.2025BMC cancer免费全文
  7. Identification of multiomics and immune infiltration-associated biomarkers for early gastric cancer: a machine learning-based diagnostic model development study.2025BMC cancer免费全文
  8. Indocyanine Green-Labeled Antibody-NOTCH2 as a New Fluorescent Molecular Imaging Probe for Gastric Cancer.2025Bioconjugate chemistry免费全文
  9. Comparing Quality of Life for Billroth II With Braun Versus Uncut Roux-en-Y Reconstruction After Total Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Clinical Trial.2025Cancer control : journal of the Moffitt Cancer CenterRCT免费全文
  10. The Black Hole of Immune Checkpoint Blocking Therapy for Gastric Cancer: Hyperprogressive Disease.2025Cancer science免费全文
  11. ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation.2025Cell death & disease免费全文
  12. Identification and Validation of a Novel Prognostic Signature of Gastric Cancer Based on Seven Complement System-Related Genes: An Integrated Analysis.2025Critical reviews in eukaryotic gene expression
  13. Integrative Analysis Reveals Differential Characteristics of DDR1 Mutant and Wild-type Gastric Cancers and Constructs their Prediction Models.2025Current medicinal chemistry
  14. Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients.2025Current treatment options in oncology
  15. Association between different patterns of obesity and the short-term outcomes of gastric cancer surgery.2025European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)免费全文
  16. Nutritional status of early oral feeding for gastric cancer patients after laparoscopic total gastrectomy: A retrospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  17. Sequential HIPEC, Claudin18.2-targeted therapy, and CapeOx chemotherapy leading to resolution of peritoneal metastases and curative resection in gastric cancer: a case report and literature review.2025Frontiers in immunology免费全文
  18. Deep learning and multi-omics reveal programmed cell death-associated diagnostic signatures and prognostic biomarkers in gastric cancer.2025Frontiers in immunology免费全文
  19. Renal capsule patient-derived xenograft model for gastric cancer: establishment and MRI characterization.2025Frontiers in immunology免费全文
  20. Targeting the BAG2/CHIP axis promotes gastric cancer apoptosis by blocking apoptosome assembly.2025Frontiers in immunology免费全文
  21. HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy.2025Frontiers in immunology免费全文
  22. Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles.2025Gene
  23. Multi-omic analysis reveals the role of coagulation factor family genes and their predictive value for immune checkpoint inhibitors efficacy in gastric cancer.2025International journal of biological macromolecules
  24. Does ambient particulate matter 1 increase the risk of gastric cancer in the northwest of China?2025International journal of cancer
  25. Clinical application value of modified overlap anastomosis for Siewert type II and III adenocarcinoma of esophagogastric junction.2025Journal of cancer research and clinical oncology免费全文
  26. Gastric cancer-derived exosomal let-7 g-5p mediated by SERPINE1 promotes macrophage M2 polarization and gastric cancer progression.2025Journal of experimental & clinical cancer research : CR免费全文
  27. Targeted DDR1 Treatment Strategy Enhances PD-1 Immunotherapy Efficacy against Gastric Cancer.2025Journal of medicinal chemistry免费全文
  28. Single-cell RNA sequencing and spatial transcriptomics reveal the heterogeneity and intercellular communication of cancer-associated fibroblasts in gastric cancer.2025Journal of translational medicine免费全文
  29. Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study.2025Med (New York, N.Y.)
  30. Effect of PRKD3 on cell cycle in gastric cancer progression and downstream regulatory networks.2025Medical oncology (Northwood, London, England)
  31. Nanomaterials in gastric cancer: pioneering precision medicine for diagnosis, therapy, and prevention.2025Medical oncology (Northwood, London, England)
  32. ELK1 modulates SF3B3 transcriptional activity to stimulate proliferation and inhibit apoptosis in gastric cancer through the activation of the MAPK pathway.2025Neoplasma
  33. The impact of GST genetic polymorphisms on the response to oxaliplatin-based chemotherapy and survival prognosis in gastric cancer patients.2025Pharmacogenomics
  34. The expression of transmembrane channel-like 5 in gastric cancer and its impact on tumor progression.2025Scientific reports免费全文
  35. SERPINE1 Facilitates Metastasis in Gastric Cancer Through Anoikis Resistance and Tumor Microenvironment Remodeling.2025Small (Weinheim an der Bergstrasse, Germany)
  36. A prospective and comparative study on improving the diagnostic accuracy of early gastric cancer based on deep convolutional neural network real-time diagnosis system (with video).2025Surgical endoscopy
  37. The role of TMEM119 in gastric adenocarcinoma and its specific effects on immunity.2025The Journal of international medical research免费全文
  38. A case of neonatal gastric teratoma complicated with occult gastrointestinal hemorrhage misdiagnosed as lymphangioma.2025The Turkish journal of pediatrics
  39. The current landscape and advances in functional-preserving gastric cancer surgery.2025World journal of surgical oncology免费全文
  40. Historical evolution and current research status of lymph node staging in gastric cancer: a review.2025World journal of surgical oncology免费全文
  41. eIF6: a promising therapeutic target for gastric carcinoma via PI3K/AKT pathway modulation.2025World journal of surgical oncology免费全文
  42. Combination of clinical and spectral-CT iodine concentration for predicting liver metastasis in gastric cancer: a preliminary study.2024Abdominal radiology (New York)
  43. Correlation of CT parameters and PD-L1 expression status in gastric cancer.2024Abdominal radiology (New York)
  44. Not all carotenoids can reduce the risk of gastric cancer: a systematic review with meta-analysis.2024BMC gastroenterology免费全文
  45. Exploring the therapeutic potential of diterpenes in gastric cancer: Mechanisms, efficacy, and clinical prospects.2024Biomolecules & biomedicine免费全文
  46. Prediction of Ki-67 expression in gastric gastrointestinal stromal tumors using histogram analysis of monochromatic and iodine images derived from spectral CT.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  47. Targeting NUF2 suppresses gastric cancer progression through G2/M phase arrest and apoptosis induction.2024Chinese medical journal免费全文
  48. Current status of neoadjuvant immunotherapy for the treatment of gastric cancer.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  49. The application of organoids in cancers associated with pathogenic infections.2024Clinical and experimental medicine免费全文
  50. Whether the use of intravenous contrast-enhanced ultrasound can improve the accuracy of T stage diagnosis of gastric cancer?2024Clinical hemorheology and microcirculation
  51. Value of spectral CT parameters in predicting the efficacy of neoadjuvant chemotherapy for gastric cancer.2024Clinical radiology
  52. Prognostic Value and Therapeutic Significance of CCL Chemokines in Gastric Cancer.2024Current medicinal chemistry
  53. Mesenchymal Stem Cells Target Gastric Cancer and Deliver Epirubicin via Tunneling Nanotubes for Enhanced Chemotherapy.2024Current stem cell research & therapy
  54. IL-17A in gastric carcinogenesis: good or bad?2024Frontiers in immunology免费全文
  55. SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report.2024Frontiers in immunology免费全文
  56. UBE2L3 expression in human gastric cancer and its clinical significance.2024Journal of cancer research and clinical oncology免费全文
  57. High expression of NOTCH2 in gastric adenocarcinoma: A novel early diagnostic target.2024Journal of gastroenterology and hepatology
  58. Biological Clock Genes are Crucial and Promising Biomarkers for the Therapeutic Targets and Prognostic Assessment in Gastric Cancer.2024Journal of gastrointestinal cancer
  59. MicroRNAs in Helicobacter pylori-infected gastric cancer: Function and clinical application.2024Pharmacological research
  60. Photodynamic therapy may salvage chemotherapy failure in gastric cancer: A case report and a literature review.2024Photodiagnosis and photodynamic therapy
  61. EGCG targeting STAT3 transcriptionally represses PLXNC1 to inhibit M2 polarization mediated by gastric cancer cell-derived exosomal miR-92b-5p.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  62. Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy.2023Abdominal radiology (New York)
  63. Risk of venous thromboembolism in patients undergoing gastric cancer surgery: a systematic review and meta-analysis.2023BMC cancer免费全文
  64. Glycosyltransferase GLT8D1 and GLT8D2 serve as potential prognostic biomarkers correlated with Tumor Immunity in Gastric Cancer.2023BMC medical genomics免费全文
  65. Organoids: Construction and Application in Gastric Cancer.2023Biomolecules免费全文
  66. PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in Gastric Cancer.2023Cancer research
  67. A novel adenosine signalling-based prognostic signature in gastric cancer and its association with cancer immune features and immunotherapy response.2023Cell biology international
  68. A nine-gene signature as prognostic biomarker in gastric cancer by bioinformatics analysis.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  69. Combined Inhibition of KIF11 and KIF15 as an Effective Therapeutic Strategy for Gastric Cancer.2023Current cancer drug targets
  70. Focusing on Helicobacter pylori infection in the elderly.2023Frontiers in cellular and infection microbiology免费全文
  71. Photodynamic therapy improves the outcome of immune checkpoint inhibitors via remodelling anti-tumour immunity in patients with gastric cancer.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  72. Epidemiology, risk areas and macro determinants of gastric cancer: a study based on geospatial analysis.2023International journal of health geographics免费全文
  73. Exploration of gastric carcinogenesis from the relationship between bile acids and intestinal metaplasia and intragastric microorganisms (H. pylori and non-H. pylori).2023Journal of cancer research and clinical oncology免费全文
  74. A practical recurrence risk model based on Lasso-Cox regression for gastric cancer.2023Journal of cancer research and clinical oncology免费全文
  75. STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer.2023Journal of cancer research and clinical oncology免费全文
  76. Predictive value of 18F-FDG PET/CT multi-metabolic parameters and tumor metabolic heterogeneity in the prognosis of gastric cancer.2023Journal of cancer research and clinical oncology免费全文
  77. The prognostic value of FAR and a novel FAR-CA125 score in resectable gastric signet ring cell carcinoma patients.2023Journal of cancer research and clinical oncology免费全文
  78. Exploring the role of PMEPA1 in gastric cancer.2023Molecular and cellular probes
  79. Exploring the role of FBXO5 in gastric cancer.2023Molecular and cellular probes
  80. High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer.2023Pathology oncology research : POR免费全文
  81. Research progress of potential factors influencing photodynamic therapy for gastrointestinal cancer.2023Photodiagnosis and photodynamic therapy
  82. MKRN2 inhibits the proliferation of gastric cancer by downregulating PKM2.2022Aging免费全文
  83. Identification of differentially expressed miRNAs derived from serum exosomes associated with gastric cancer by microarray analysis.2022Clinica chimica acta; international journal of clinical chemistry
  84. Combination of clinical and spectral-CT parameters for predicting lymphovascular and perineural invasion in gastric cancer.2022Diagnostic and interventional imaging
  85. Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer.2022Disease markers免费全文
  86. The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer.2022Experimental cell research
  87. MCEMP1 is a potential therapeutic biomarker associated with immune infiltration in advanced gastric cancer microenvironment.2022Gene
  88. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.2022International journal of biological sciences免费全文
  89. Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.2022Japanese journal of clinical oncology
  90. Long non-coding RNA TNK2 AS1/microRNA-125a-5p axis promotes tumor growth and modulated phosphatidylinositol 3 kinase/AKT pathway.2022Journal of gastroenterology and hepatology
  91. NCAPH regulates gastric cancer progression through DNA damage response.2022Neoplasma
  92. Photodynamic Therapy in Combination with Chemotherapy, Targeted, and Immunotherapy As a Successful Therapeutic Approach for Advanced Gastric Adenocarcinoma: A Case Report and Literature Review.2022Photobiomodulation, photomedicine, and laser surgery
  93. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer.2022Science advances免费全文
  94. Clinico-radiological nomogram for preoperatively predicting post-resection hepatic metastasis in patients with gastric adenocarcinoma.2022The British journal of radiologyRCT免费全文
  95. Single-cell landscape reveals active cell subtypes and their interaction in the tumor microenvironment of gastric cancer.2022Theranostics免费全文
  96. Study on the expression of c-Met in gastric cancer and its correlation with preoperative serum tumor markers and prognosis.2022World journal of surgical oncology免费全文
  97. Immune Cell Landscape in Gastric Cancer.2021BioMed research international免费全文
  98. Long intergenic noncoding RNA00265 promotes proliferation of gastric cancer via the microRNA-144-3p/Chromobox 4 axis.2021Bioengineered免费全文
  99. Prognostic Value of lncRNA PVT1 for Patients with Gastric Cancer: A Meta-Analysis.2021Disease markers免费全文
  100. Construction and Validation of a Novel Prognostic Signature for Intestinal Type of Gastric Cancer.2021Disease markers免费全文
  101. Auditory and Visual Stimulation for Abdominal Postoperative Patients Experiencing Enhanced Recovery After Surgery (ERAS).2021Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and AssociatesRCT
  102. Prognostic Value of Combination of Inflammatory and Tumor Markers in Resectable Gastric Cancer.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  103. Damage Control Surgery Saves Patient with Gastric Lymphoma from Radical Gastrectomy.2021Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  104. Carcinosarcoma and sarcomatoid carcinoma of the stomach: Two case reports.2021Medicine免费全文
  105. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.2021Nature communications免费全文
  106. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination.2021Oncogene免费全文
  107. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer.2021Oncoimmunology免费全文
  108. Evidence Mapping of Proton Therapy, Heavy Ion Therapy, and Helical Tomotherapy for Gastric Cancer.2021Oncology research and treatment
中文论文(未计入)3
  1. Research progress in effects of MAGE-A family on gastric cancer.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  2. [Correlations of 18F-FDG PET/CT Metabolic Parameters and Metabolic Heterogeneity with Human Epidermal Growth Factor Receptor 2 Expression in Patients with Gastric Cancer].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  3. [Spectral CT multi-parameter imaging in preoperatively evaluation the status of lymphovascular and perineural invasion of gastric cancer].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  2. Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma正在招募NCT06949033研究中心III期2025-05 启动
  3. Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer正在招募NCT07029269研究中心III期2025-06 启动
  4. Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma正在招募NCT06925243研究中心III期2025-04 启动
  5. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  6. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  7. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  8. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  9. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  10. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma已终止NCT04718402研究中心I期2021-03 启动
  11. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  12. Comparing the Prognosis of Patients With Cardia and Non-cardia Gastric Cancer.状态不明NCT03895008研究中心2019-07 启动
  13. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer进行中,不再招募NCT04208347研究中心II/III期2019-12 启动
  14. Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer状态不明NCT03410732研究中心II期2017-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

兰州有 2 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.7%。

牵头论文
15
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 5520222023: 2220232024: 3320242025: 332025

兰州有 8 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文15
  1. Long non-coding RNA BCAR4 regulates osteosarcoma progression by targeting microRNA-1260a.2025Bulletin du cancer
  2. Thermo-responsive nano-hydrogel-based delivery of Saikosaponin a to enhance anti-PD-1 therapy in osteosarcoma.2025Nanomedicine (London, England)
  3. PDK1, associated with glycolytic metabolism, is a potential prognostic biomarker in osteosarcoma.2025PloS one
  4. The Role of Ubiquitination in Osteosarcoma Development and Therapies.2024Biomolecules
  5. Ferroptosis defense mechanisms: The future and hope for treating osteosarcoma.2024Cell biochemistry and function
  6. Circ_0004674 regulation of glycolysis and proliferation mechanism of osteosarcoma through miR-140-3p/TCF4 pathway.2024Journal of biochemical and molecular toxicology
  7. Silencing circular RNA hsa_circABCC1 inhibits osteosarcoma progression through down-regulating HDAC4 via sponging miR-591.2023Environmental toxicology
  8. Research Progress of Nanomaterials in Chemotherapy of Osteosarcoma.2023Orthopaedic surgery
  9. The value of Ki-67 as a prognostic biomarker in osteosarcoma: A systematic review and meta-analysis.2022Asian journal of surgery
  10. Extraosseous Ewing's sarcoma/peripheral primitive neuroectodermal tumour of the kidney: a case report and literature review.2022BMC urology
  11. Roles of MET in human cancer.2022Clinica chimica acta; international journal of clinical chemistry
  12. KMT5A Knockdown Suppresses Osteosarcoma Cell Proliferation and Metastasis Through Ꞵ-Catenin Signalling.2022Clinical and investigative medicine. Medecine clinique et experimentale
  13. TRIP13 knockdown inhibits the proliferation, migration, invasion, and promotes apoptosis by suppressing PI3K/AKT signaling pathway in U2OS cells.2022Molecular biology reports
  14. Comparative analysis of magnetic resonance imaging and pathological findings of microcystic meningioma and meningeal Ewing sarcoma/peripheral primitive neuroectodermal tumors.2021Acta neurologica Belgica
  15. Exosomal miR-21-5p derived from bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion by targeting PIK3R1.2021Journal of cellular and molecular medicine
早期论文(2016–2020 年)9
  1. Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma.2020Molecular medicine reports
  2. Silencing of RIPK4 inhibits epithelial‑mesenchymal transition by inactivating the Wnt/β‑catenin signaling pathway in osteosarcoma.2020Molecular medicine reports
  3. Rosmarinic acid exerts an anticancer effect on osteosarcoma cells by inhibiting DJ-1 via regulation of the PTEN-PI3K-Akt signaling pathway.2020Phytomedicine : international journal of phytotherapy and phytopharmacology
  4. HOXA5 overexpression promotes osteosarcoma cell apoptosis through the p53 and p38α MAPK pathway.2019Gene
  5. COX‑2 promotes epithelial‑mesenchymal transition and migration in osteosarcoma MG‑63 cells via PI3K/AKT/NF‑κB signaling.2019Molecular medicine reports
  6. WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway.2018Cell biology international
  7. Pelargonidin induces antitumor effects in human osteosarcoma cells via autophagy induction, loss of mitochondrial membrane potential, G2/M cell cycle arrest and downregulation of PI3K/AKT signalling pathway.2018Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  8. Exosomes Derived from Human Bone Marrow Mesenchymal Stem Cells Promote Tumor Growth Through Hedgehog Signaling Pathway.2017Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  9. Long Noncoding RNA GAS5 Suppresses Cell Growth and Epithelial-Mesenchymal Transition in Osteosarcoma by Regulating the miR-221/ARHI Pathway.2017Journal of cellular biochemistry

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.0%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 112025

兰州有 3 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

兰州有 1 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

兰州有 4 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.7%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 2220242025: 442025

兰州有 3 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层双抗与抗体药物
论文中的科室影像/核医学科病理/检验科肿瘤内科消化/肝病科
牵头的论文12
  1. Analysis of discordant results in multi-technique platform-based MRD detection in multiple myeloma and the clinical decision-making dilemma.2026Leukemia & lymphoma
  2. Magnetic resonance imaging-based nomograms predict high-risk cytogenetic abnormalities in multiple myeloma: a two-centre study.2025Clinical radiology
  3. Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis.2025Current problems in cancer
  4. Threonine and tyrosine kinase promotes multiple myeloma progression by regulating regucalcin expression.2025Experimental cell research
  5. Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration.2025Scientific reports免费全文
  6. Construction of the prediction model for multiple myeloma based on machine learning.2024International journal of laboratory hematology
  7. Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort.2024Nucleosides, nucleotides & nucleic acids
  8. LGR4 promotes tumorigenesis by activating TGF-β1/Smad signaling pathway in multiple myeloma.2023Cellular signalling
  9. Obesity as a risk factor for multiple myeloma: insight on the role of adipokines.2023Pathology oncology research : POR免费全文
  10. The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.2022Frontiers in immunology免费全文
  11. Nontargeted and targeted metabolomics approaches reveal the key amino acid alterations involved in multiple myeloma.2022PeerJ免费全文
  12. Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis.2021The Journal of international medical research免费全文
中文论文(未计入)6
  1. [Prognosis and immune biomarkers of multiple myeloma].2024Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  2. [Prognostic Value of A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  3. [A Prognostic Nomogram Based on Response to Bortezomib and BTK Expression for Treatment-Experienced Multiple Myeloma Patients].2022Zhongguo shi yan xue ye xue za zhi
  4. [Clinical Significance of sFLC/MP Level and Light Chain Escape in Patients with Multiple Myeloma Relapse].2021Zhongguo shi yan xue ye xue za zhi
  5. [The Influence of CONUT Score on the Prognosis of Patients with Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  6. [Multiple myeloma with multiple extramedullary lesions of pancreas, stomach and skin: a case report].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  2. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

兰州有 1 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题诊断与鉴别肾脏、腹膜后与血管治疗与复发

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

兰州有 1 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题孕期、儿童与老人
论文中的科室神经内科
牵头的论文2
  1. Autoimmune polyendocrine syndrome type 2 in children: a case report and literature review.2025BMC pediatrics免费全文
  2. Wernicke encephalopathy, myasthenia gravis, or both?2022Panminerva medica
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

兰州有 1 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

兰州有 1 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科
中文论文(未计入)1
  1. [A case of Takayasu arteritis complicated with cavernous sinus syndrome presenting as unilateral optic nerve DWI hyperintensity].2024[Zhonghua yan ke za zhi] Chinese journal of ophthalmology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年没有牵头特发性肺纤维化的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

兰州有 3 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Progress in sleep-disordered breathing in idiopathic pulmonary fibrosis].2017Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

兰州有 2 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

兰州有 3 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
牵头的论文2
  1. Identification of risk factors for renal progression in adults with IgAV: a retrospective cohort study of a single center in northwest China.2025International urology and nephrology
  2. Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy.2024BMC nephrology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  2. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

兰州有 1 家医院列在戈谢病下全国有 41 家医院列在戈谢病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease已完成NCT05529992研究中心III期2023-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

兰州有 1 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    分期
    III期
    开始
    2023-02
    登记号
    NCT05751967

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 6 家列出的医院为研究中心兰州、南京、天津、广州、成都、沈阳、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis正在招募NCT05751967研究中心III期2023-02 启动
  2. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis进行中,不再招募NCT06174402研究中心II/III期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

兰州有 2 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

兰州大学第二医院

Lanzhou University Second Hospital

兰州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Second Hospital of Lanzhou University; Lanzhou University Second hospital; Xigu Branch of the Second Hospital of Lanzhou University; Lanzhou University Second Clinical Medical College

提出更正下载数据